Results 71 to 80 of about 10,095 (153)

Falla cardiaca asociada con el uso de imatinib mesilato: Reporte de un caso Heart failure associated to imatinib mesylate use: Case report

Revista Colombiana de Cardiología, 2008
La cardiotoxicidad por medicamentos es un evento cada vez más frecuente en la práctica clínica diaria. Inhibidores de la proteína de fusión Brc/Abl como el imatinib mesilato, son una nueva herramienta para el tratamiento de algunas neoplasias ...
Clara Saldarriaga, Jairo A Rendón, Juan M Senior   +2 more
doaj  

Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes

Drug Design, Development and Therapy, 2017
Ali Kadivar,1 Behnam Kamalidehghan,1 Hamid Akbari Javar,2 Benyamin Karimi,3 Reihaneh Sedghi,4 Mohamed Ibrahim Noordin1 1Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 2Department of Pharmaceutics, Faculty of ...
Kadivar A, Kamalidehghan B, Akbari Javar H, Karimi B, Sedghi R, MI Noordin   +5 more
doaj  

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia

Brazilian Journal of Pharmaceutical Sciences
Adherence to imatinib mesylate improves clinical outcomes and promotes a reduction in health expenditure. However, treatment duration and lack of efficacy decrease adherence to pharmacotherapy, resulting in increased mortality associated with Chronic ...
Alexandra Rodrigues Alves, William Gustavo Lima, Michelly Martins Nagai, João Paulo Vilela Rodrigues, Lorena Rocha Ayres   +4 more
doaj   +1 more source

Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate. [PDF]

Cureus, 2023
Batra J, Ankireddypalli AR, Kanugula AK, Gorle S, Kaur J.   +4 more
europepmc   +1 more source

Kaposi's sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy. [PDF]

Clin Case Rep, 2022
D'Addona M, Pezzullo L, Giudice V, Serio B, Baldi C, Zeppa P, Selleri C.   +6 more
europepmc   +1 more source

Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response. [PDF]

Ann Hematol, 2023
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I.   +11 more
europepmc   +1 more source

Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells. [PDF]

Iran J Basic Med Sci, 2023
Kamyabi R, Jahandideh A, Panahi N, Muhammadnejad S.   +3 more
europepmc   +1 more source

The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas. [PDF]

PLoS Pathog, 2023
Cleverley TL, Peddineni S, Guarner J, Cingolani F, Garcia PK, Koehler H, Mocarski ES, Kalman D.   +7 more
europepmc   +1 more source

Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response. [PDF]

Ann Hematol, 2023
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I.   +11 more
europepmc   +1 more source

Correction: Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet. [PDF]

PLoS One, 2022
PLOS ONE Editors.
europepmc   +1 more source